Advanced bronchioloalveolar carcinoma

A phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): A Southwest Oncology Group study

Howard L. West, J. J. Crowley, R. B. Vance, W. A. Franklin, Robert B Livingston, S. R. Dakhil, J. K. Giguere, S. E. Rivkin, M. Kraut, K. Chansky, D. R. Gandara

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background: There are no published prospective trials of chemotherapy for advanced bronchioloalveolar carcinoma (BAC), a subtype of non-small-cell lung cancer for which there is no current standard therapy. This phase II study assesses the efficacy and toxicity of 96-h paclitaxel in chemotherapy-naive patients with advanced BAC. Patients and methods: Patients with histologically confirmed stage IIIB (with pleural effusion) or stage IV BAC were eligible. Treatment consisted of paclitaxel 35 mg/m2/24 h continuously infused over 96 h (days 1-4) every 21 days for up to six courses. Results: A total of 58 eligible patients were enrolled. The objective response rate was 14% (all partial responses, 9% confirmed); 40% of patients demonstrated stable disease. The median progression-free and overall survivals were 5 and 12 months, respectively. Grade 3 or greater toxicities included neutropenia/granulocytopenia (43%), febrile neutropenia (12%), infection (22%), and stomatitis/pharyngitis (10%); there were five treatment-related deaths. Conclusions: S9714 represents the first prospective multi-institutional cooperative group trial focusing on treatment outcomes in BAC. Studies targeting this population are feasible, and while first-line paclitaxel administered as a prolonged infusion is active in this setting, toxicities limits the utility of this regimen. S9714 serves as a historical control for BAC patients against which future therapeutic approaches can be compared.

Original languageEnglish (US)
Pages (from-to)1076-1080
Number of pages5
JournalAnnals of Oncology
Volume16
Issue number7
DOIs
StatePublished - Jul 2005
Externally publishedYes

Fingerprint

Bronchiolo-Alveolar Adenocarcinoma
Paclitaxel
Drug Therapy
Febrile Neutropenia
Stomatitis
Agranulocytosis
Pharyngitis
Pleural Effusion
Therapeutics
Neutropenia
Non-Small Cell Lung Carcinoma
Disease-Free Survival
Infection
Population

Keywords

  • Bronchioloalveolar carcinoma
  • Non-small lung cancer
  • Paclitaxel
  • Prolonged infusion

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Advanced bronchioloalveolar carcinoma : A phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): A Southwest Oncology Group study. / West, Howard L.; Crowley, J. J.; Vance, R. B.; Franklin, W. A.; Livingston, Robert B; Dakhil, S. R.; Giguere, J. K.; Rivkin, S. E.; Kraut, M.; Chansky, K.; Gandara, D. R.

In: Annals of Oncology, Vol. 16, No. 7, 07.2005, p. 1076-1080.

Research output: Contribution to journalArticle

West, HL, Crowley, JJ, Vance, RB, Franklin, WA, Livingston, RB, Dakhil, SR, Giguere, JK, Rivkin, SE, Kraut, M, Chansky, K & Gandara, DR 2005, 'Advanced bronchioloalveolar carcinoma: A phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): A Southwest Oncology Group study', Annals of Oncology, vol. 16, no. 7, pp. 1076-1080. https://doi.org/10.1093/annonc/mdi215
West, Howard L. ; Crowley, J. J. ; Vance, R. B. ; Franklin, W. A. ; Livingston, Robert B ; Dakhil, S. R. ; Giguere, J. K. ; Rivkin, S. E. ; Kraut, M. ; Chansky, K. ; Gandara, D. R. / Advanced bronchioloalveolar carcinoma : A phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): A Southwest Oncology Group study. In: Annals of Oncology. 2005 ; Vol. 16, No. 7. pp. 1076-1080.
@article{05399a353eab4f6d94a2d24494fd7f33,
title = "Advanced bronchioloalveolar carcinoma: A phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): A Southwest Oncology Group study",
abstract = "Background: There are no published prospective trials of chemotherapy for advanced bronchioloalveolar carcinoma (BAC), a subtype of non-small-cell lung cancer for which there is no current standard therapy. This phase II study assesses the efficacy and toxicity of 96-h paclitaxel in chemotherapy-naive patients with advanced BAC. Patients and methods: Patients with histologically confirmed stage IIIB (with pleural effusion) or stage IV BAC were eligible. Treatment consisted of paclitaxel 35 mg/m2/24 h continuously infused over 96 h (days 1-4) every 21 days for up to six courses. Results: A total of 58 eligible patients were enrolled. The objective response rate was 14{\%} (all partial responses, 9{\%} confirmed); 40{\%} of patients demonstrated stable disease. The median progression-free and overall survivals were 5 and 12 months, respectively. Grade 3 or greater toxicities included neutropenia/granulocytopenia (43{\%}), febrile neutropenia (12{\%}), infection (22{\%}), and stomatitis/pharyngitis (10{\%}); there were five treatment-related deaths. Conclusions: S9714 represents the first prospective multi-institutional cooperative group trial focusing on treatment outcomes in BAC. Studies targeting this population are feasible, and while first-line paclitaxel administered as a prolonged infusion is active in this setting, toxicities limits the utility of this regimen. S9714 serves as a historical control for BAC patients against which future therapeutic approaches can be compared.",
keywords = "Bronchioloalveolar carcinoma, Non-small lung cancer, Paclitaxel, Prolonged infusion",
author = "West, {Howard L.} and Crowley, {J. J.} and Vance, {R. B.} and Franklin, {W. A.} and Livingston, {Robert B} and Dakhil, {S. R.} and Giguere, {J. K.} and Rivkin, {S. E.} and M. Kraut and K. Chansky and Gandara, {D. R.}",
year = "2005",
month = "7",
doi = "10.1093/annonc/mdi215",
language = "English (US)",
volume = "16",
pages = "1076--1080",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Advanced bronchioloalveolar carcinoma

T2 - A phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): A Southwest Oncology Group study

AU - West, Howard L.

AU - Crowley, J. J.

AU - Vance, R. B.

AU - Franklin, W. A.

AU - Livingston, Robert B

AU - Dakhil, S. R.

AU - Giguere, J. K.

AU - Rivkin, S. E.

AU - Kraut, M.

AU - Chansky, K.

AU - Gandara, D. R.

PY - 2005/7

Y1 - 2005/7

N2 - Background: There are no published prospective trials of chemotherapy for advanced bronchioloalveolar carcinoma (BAC), a subtype of non-small-cell lung cancer for which there is no current standard therapy. This phase II study assesses the efficacy and toxicity of 96-h paclitaxel in chemotherapy-naive patients with advanced BAC. Patients and methods: Patients with histologically confirmed stage IIIB (with pleural effusion) or stage IV BAC were eligible. Treatment consisted of paclitaxel 35 mg/m2/24 h continuously infused over 96 h (days 1-4) every 21 days for up to six courses. Results: A total of 58 eligible patients were enrolled. The objective response rate was 14% (all partial responses, 9% confirmed); 40% of patients demonstrated stable disease. The median progression-free and overall survivals were 5 and 12 months, respectively. Grade 3 or greater toxicities included neutropenia/granulocytopenia (43%), febrile neutropenia (12%), infection (22%), and stomatitis/pharyngitis (10%); there were five treatment-related deaths. Conclusions: S9714 represents the first prospective multi-institutional cooperative group trial focusing on treatment outcomes in BAC. Studies targeting this population are feasible, and while first-line paclitaxel administered as a prolonged infusion is active in this setting, toxicities limits the utility of this regimen. S9714 serves as a historical control for BAC patients against which future therapeutic approaches can be compared.

AB - Background: There are no published prospective trials of chemotherapy for advanced bronchioloalveolar carcinoma (BAC), a subtype of non-small-cell lung cancer for which there is no current standard therapy. This phase II study assesses the efficacy and toxicity of 96-h paclitaxel in chemotherapy-naive patients with advanced BAC. Patients and methods: Patients with histologically confirmed stage IIIB (with pleural effusion) or stage IV BAC were eligible. Treatment consisted of paclitaxel 35 mg/m2/24 h continuously infused over 96 h (days 1-4) every 21 days for up to six courses. Results: A total of 58 eligible patients were enrolled. The objective response rate was 14% (all partial responses, 9% confirmed); 40% of patients demonstrated stable disease. The median progression-free and overall survivals were 5 and 12 months, respectively. Grade 3 or greater toxicities included neutropenia/granulocytopenia (43%), febrile neutropenia (12%), infection (22%), and stomatitis/pharyngitis (10%); there were five treatment-related deaths. Conclusions: S9714 represents the first prospective multi-institutional cooperative group trial focusing on treatment outcomes in BAC. Studies targeting this population are feasible, and while first-line paclitaxel administered as a prolonged infusion is active in this setting, toxicities limits the utility of this regimen. S9714 serves as a historical control for BAC patients against which future therapeutic approaches can be compared.

KW - Bronchioloalveolar carcinoma

KW - Non-small lung cancer

KW - Paclitaxel

KW - Prolonged infusion

UR - http://www.scopus.com/inward/record.url?scp=25444442802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444442802&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdi215

DO - 10.1093/annonc/mdi215

M3 - Article

VL - 16

SP - 1076

EP - 1080

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -